Andreev et al. constructed a bispecific ADC that bridges HER2 and the prolactin receptor (PRLR), which can co-target PRLR on the surface of HER2-positive tumor cells, leading to significantly enhanced internalization and killing effects of the ADC in tumors co-expressing HER2 and PRLR[137]. Here, PRLR is linked to neoplasm.